Department of Ophthalmology, NTT East Japan Tohoku Hospital, Sendai, Miyagi, Japan.
Retina. 2011 Apr;31(4):748-54. doi: 10.1097/IAE.0b013e3181f04991.
To evaluate the effectiveness of intravitreal triamcinolone acetonide (IVTA) on the reduction of diffuse diabetic macular edema with different optical coherence tomographic patterns.
One hundred and thirty-five eyes with diffuse diabetic macular edema without any treatment that had received a single dose (4 mg in 0.1 mL) of IVTA were retrospectively examined. Each preoperative macular optical coherence tomographic image was classified according to its appearance as follows: sponge-like diffuse retinal thickening, cystoid macular edema (CME), and serous retinal detachment (SRD). Central macular thickness with optical coherence tomographic images and visual acuity with a logarithm of the minimum angle of resolution chart were assessed at 3 months postoperatively.
Of 135 eligible eyes, 49 eyes were identified as having only sponge-like diffuse retinal thickening, 45 eyes with CME, and 26 eyes with SRD. Of those 135 eyes, 15 eyes exhibited the combination of all types of diffuse diabetic macular edema, defined as FULL. After IVTA, central macular thickness was reduced to 31.0 ± 15.9% in the sponge-like diffuse retinal thickening, 40.7 ± 14.2% in the CME, 23.4 ± 15.0% in the SRD, and 25.8 ± 14.8% in the FULL group (P < 0.001; one-factor analysis of variance), while improvement in logarithm of the minimum angle of resolution visual acuity was -0.26 ± 0.21 in the sponge-like diffuse retinal thickening, -0.32 ± 0.20 in the CME, -0.17 ± 0.20 in the SRD, and -0.14 ± 0.22 in the FULL group (P = 0.018; one-factor analysis of variance).
The effectiveness of IVTA on diffuse diabetic macular edema was dependent on the optical coherence tomographic pattern, and IVTA was found to be more effective in patients with CME, while IVTA was less effective in those with SRD.
评估玻璃体内曲安奈德(IVTA)注射对不同光学相干断层扫描(OCT)模式下弥漫性糖尿病性黄斑水肿消退的疗效。
对 135 例未经任何治疗且已接受单剂量(0.1 mL 中 4 mg)IVTA 治疗的弥漫性糖尿病性黄斑水肿患者进行回顾性检查。根据术前黄斑 OCT 图像的表现,将每例患者分为以下几种类型:海绵状弥漫性视网膜增厚、囊样黄斑水肿(CME)和浆液性视网膜脱离(SRD)。术后 3 个月,用 OCT 评估中心黄斑厚度,用最小分辨角对数视力表评估视力。
在 135 例符合条件的眼中,49 只眼仅有海绵状弥漫性视网膜增厚,45 只眼有 CME,26 只眼有 SRD。在这 135 只眼中,有 15 只眼表现出所有类型弥漫性糖尿病性黄斑水肿的组合,定义为 FULL 组。玻璃体内注射曲安奈德后,海绵状弥漫性视网膜增厚组、CME 组、SRD 组和 FULL 组的中心黄斑厚度分别减少至 31.0±15.9%、40.7±14.2%、23.4±15.0%和 25.8±14.8%(P<0.001;单因素方差分析),而对数最小分辨角视力的改善在海绵状弥漫性视网膜增厚组、CME 组、SRD 组和 FULL 组分别为-0.26±0.21、-0.32±0.20、-0.17±0.20 和-0.14±0.22(P=0.018;单因素方差分析)。
玻璃体内曲安奈德对弥漫性糖尿病性黄斑水肿的疗效取决于 OCT 模式,对 CME 患者疗效更显著,而对 SRD 患者疗效较差。